|
1
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75:191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al:
Metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
27:v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu G, Pei F, Yang F, Li L, Amin AD, Liu
S, Buchan JR and Cho WC: Role of autophagy and apoptosis in
non-small-cell lung cancer. Int J Mol Sci. 18:E3672017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Payandeh M, Sadeghi M, Sadeghi E and
Aeinfar M: The survival of lung cancer based on type of treatment
in non-small-cell lung cancer: A review of literatureInternational
Congress on Anti-Cancer Treatment. Paris, France: 2015
|
|
5
|
Lim BJ, Jung SS, Choi SY and Lee CS:
Expression of metastasis-associated molecules in non-small cell
lung cancer and their prognostic significance. Mol Med Rep.
3:43–49. 2010.PubMed/NCBI
|
|
6
|
Müllertidow C, Diederichs S, Bulk E, Pohle
T, Steffen B, Schwäble J, Plewka S, Thomas M, Metzger R, Schneider
PM, et al: Identification of metastasis-associated receptor
tyrosine kinases in non-small cell lung cancer. Cancer Res.
65:1778–1782. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schoenberger SD, Kim SJ, Sheng J, Rezaei
KA, Lalezary M and Cherney E: Increased prostaglandin E2 (PGE2)
levels in proliferative diabetic retinopathy, and correlation with
VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci.
53:5906–5911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chell S, Kaidi A, Kadi A, Williams AC and
Paraskeva C: Mediators of PGE2 synthesis and signalling downstream
of COX-2 represent potential targets for the prevention/treatment
of colorectal cancer. Biochim Biophys Acta. 1766:104–119.
2006.PubMed/NCBI
|
|
9
|
Li Z, Zhang Y, Wanju K and Yehia D: PGE2
promotes renal carcinoma cell invasion through activated RalA.
Oncogene. 32:1408–1415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim CH, Park YG, Noh SH and Kim YK: PGE2
induces the gene expression of bone matrix metalloproteinase-1 in
mouse osteoblasts by cAMP-PKA signaling pathway. Int J Biochem Cell
Biol. 37:375–385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dajani OF, Meisdalen K, Guren TK, Aasrum
M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D and
Christoffersen T: Prostaglandin E2 upregulates EGF-stimulated
signaling in mitogenic pathways involving Akt and ERK in
hepatocytes. J Cell Physiol. 214:371–380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goulet JL, Pace AJ, Key ML, Byrum RS,
Nguyen M, Tilley SL, Morham SG, Langenbach R, Stock JL, McNeish JD,
et al: E-prostanoid-3 receptors mediate the proinflammatory actions
of prostaglandin E2 in acute cutaneous inflammation. J Immunol.
173:1321–1326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen L, Miao Y, Zhang Y, Dou D, Liu L,
Tian X, Yang G, Pu D, Zhang X, Kang J, et al: Inactivation of the
E-prostanoid 3 receptor attenuates the angiotensin II pressor
response via decreasing arterial contractility. Arterioscler Thromb
Vasc Biol. 32:3024–3032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miyata Y, Ohba K, Matsuo T, Watanabe S,
Hayashi T, Sakai H and Kanetake H: Tumor-associated stromal cells
expressing E-prostanoid 2 or 3 receptors in prostate cancer:
Correlation with tumor aggressiveness and outcome by angiogenesis
and lymphangiogenesis. Urology. 81:136–142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reader J, Holt D and Fulton A:
Prostaglandin E 2 EP receptors as therapeutic targets in breast
cancer. Cancer Metastasis Rev. 30:449–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amano H, Ito Y, Suzuki T, Kato S, Matsui
Y, Ogawa F, Murata T, Sugimoto Y, Senior R, Kitasato H, et al:
Roles of a prostaglandin E-type receptor, EP3, in upregulation of
matrix metalloproteinase-9 and vascular endothelial growth factor
during enhancement of tumor metastasis. Cancer Sci. 100:2318–2324.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang T, Hou J, He M, Wang L, Zheng M, Wang
X and Xia J: Actinidia chinensis Planch root extract (acRoots)
inhibits hepatocellular carcinoma progression by inhibiting EP3
expression. Cell Biol Toxicol. 32:499–511. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang C, Wang Q, Xu Z, Li WS, Chen C, Yao
XQ and Liu FK: Cyclooxygenase-2 knockdown using retinoic acid
chalcone (RAC), a promising therapeutic strategy for colon cancer.
Am J Cancer Res. 5:2012–2021. 2015.PubMed/NCBI
|
|
19
|
Yano T, Zissel G, Muller-Qernheim J, Shin
Jae S, Satoh H and Ichikawa T: Prostaglandin E-2 reinforces the
activation of Ras signal pathway in lung adenocarcinoma cells via
EP3. FEBS Lett. 518:154–158. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamaki T, Endoh KM, Miyahara M, Nagamine
I, Thi Thu, Huong N, Sakurai H, Pokorny J and Yano T: Prostaglandin
E2 activates Src signaling in lung adenocarcinoma cell via EP3.
Cancer Lett. 214:115–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Israel DD and Regan JW: EP(3) prostanoid
receptor isoforms utilize distinct mechanisms to regulate ERK 1/2
activation. Biochim Biophys Acta. 1791:238–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang P, Zhu F, Lee NH and Konstantopoulos
K: Shear-induced interleukin-6 synthesis in chondrocytes: Roles of
E Prostanoid (EP) 2 and EP3 in cAMP/protein KINASE A- and
PI3-K/Akt-dependent NF-κB activation. J Biol Chem. 285:24793–24804.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Levy L and Hill CS: Alterations in
components of the TGF-beta superfamily signaling pathways in human
cancer. Cytokine Growth Factor Rev. 17:41–58. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Massagué J and Wotton D: Transcriptional
control by the TGF-beta/Smad signaling system. EMBO J.
19:1745–1754. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Massagué J: How cells read TGF-beta
signals. Nat Rev Mol Cell Biol. 1:169–178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zu L, Xue Y and Wang J, Fu Y, Wang X, Xiao
G, Hao M, Sun X, Wang Y, Fu G and Wang J: The feedback loop between
miR-124 and TGF-β pathway plays a significant role on non-small
cell lung cancer metastasis. Carcinogenesis. 37:333–343. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Yi J, Chen X, Zhang Y, XU M and
Yang Z: The regulation of cancer cell migration by lung cancer
cell-derived exosomes through TGF-β and IL-10. Oncol Lett.
11:1527–1530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu A, Zuo C, He Y, Chen G, Piao L, Zhang
J, Xiao B, Shen Y, Tang J, Kong D, et al: EP3 receptor deficiency
attenuates pulmonary hypertension through suppression of Rho/TGF-β1
signaling. J Clin Invest. 125:1228–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang JX, Zhai JF, Yang XT and Wang J:
MicroRNA-132 inhibits migration, invasion and
epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in
human non-small cell lung cancer. Eur Rev Med Pharmacol Sci.
20:3793–3801. 2016.PubMed/NCBI
|
|
32
|
Da C, Liu Y, Zhan Y, Liu K and Wang R:
Nobiletin inhibits epithelial-mesenchymal transition of human
non-small cell lung cancer cells by antagonizing the TGF-β1/Smad3
signaling pathway. Oncol Rep. 35:2767–2774. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang X, Li M, Hu M, Wei P and Zhu W: BAMBI
overexpression together with β-sitosterol ameliorates NSCLC via
inhibiting autophagy and inactivating TGF-β/Smad2/3 pathway. Oncol
Rep. 37:3046–3054. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Prescott SM and Fitzpatrick FA:
Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta.
1470:M69–M78. 2000.PubMed/NCBI
|
|
35
|
Dufour M, Faes S, Dormond-Meuwly A,
Demartines N and Dormond O: PGE2-induced colon cancer growth is
mediated by mTORC1. Biochem Biophys Res Commun. 451:587–591. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bocca C, Ievolella M, Autelli R, Motta M,
Mosso L, Torchio B, Bozzo F, Cannito S, Paternostro C, Colombatto
S, et al: Expression of Cox-2 in human breast cancer cells as a
critical determinant of epithelial-to-mesenchymal transition and
invasiveness. Exp Opin Ther Targets. 18:121–135. 2014. View Article : Google Scholar
|
|
37
|
Sharma S, Yang SC, Zhu L, Reckamp K,
Gardner B, Baratelli F, Huang M, Batra RK and Dubinett SM: Tumor
cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3
expression and CD4+ CD25+ T regulatory cell activities in lung
cancer. Cancer Res. 65:5211–5220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pan J, Yang Q, Shao J, Zhang L, Ma J, Wang
Y, Jiang BH, Leng J and Bai X: Cyclooxygenase-2 induced β1-integrin
expression in NSCLC and promoted cell invasion via the
EP1/MAPK/E2F-1/FoxC2 signal pathway. Sci Rep. 6:338232016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Amano H, Hayashi I, Endo H, Kitasato H,
Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto
Y, et al: Host prostaglandin E2-EP3 signaling regulates
tumor-associated angiogenesis and tumor growth. J Exp Med.
197:221–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shen JL, Yan CH, Liu Y, Yan XQ, Zhang XL,
Jin Y, Zhang KF, Sang ZF, Zhang GY, Li P and Fu SB: Studies of
TGF-β/Smads expression in lung cancer. Yi Chuan Xue Ba. 30:681–686.
2003.(In Chinese).
|
|
41
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
